Compare DuPont de Nemours Inc (DD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Revvity Inc — how do they compare? DuPont de Nemours Inc trades at $134.41 (market cap $18.12B), while Revvity Inc trades at $110.91 (market cap $12.41B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and DuPont de Nemours Inc pays the higher dividend (1.79%). Which is the better fit depends on your goals.
| DD | RVTY | |
|---|---|---|
Market Cap | $18.12B | $12.41B |
Sector | Basic Materials | Technology |
52-Week High | $154.59 | $117.75 |
52-Week Low | $87.72 | $82.26 |
Enterprise Value | $20.58B | $14.90B |
Dividend Yield | 1.79% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.66, down 1.5% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (35.01%) but negative net income margin (-0.42%) and ROE (-0.16%). Analyst consensus remains bullish with a $227.20 price target (71% upside), though the company faces legal challenges and persistent net cash outflows. Recent developments include water technology upgrades and a 3:1 reverse stock split effective June 2026.
While analyst optimism and valuation discount to price target suggest potential upside, investors face significant risks including ongoing litigation over 'forever chemicals,' weak profitability trends, and concerning cash flow patterns. The stock's current technical weakness near support levels requires careful monitoring of Q2 2026 earnings results due July 2026.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
